Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants

Model scores of the 29,894 trials active now.

Model score 30% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (369 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-01-19. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: long termterm safetytolerabilitysafety andthe long
  Phrases that lowered it: participantsparticipantefficacyaccordingthe treatment
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 3.6% (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Blinding: none (raises risk) · Design
• Sponsor's past trials: 28 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Disease area, dermatology: Yes (raises risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Disease area, musculoskeletal: Yes (raises risk) · Disease area
• Allocation: non randomized (raises risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis NCT03025308 · started 2017 · scored riskier than 87% of active trials completed
• An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis. NCT03320876 · started 2017 · scored riskier than 83% of active trials terminated
• Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy NCT04115748 · started 2019 · scored riskier than 25% of active trials terminated
• A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib NCT03823378 · started 2019 · scored riskier than 20% of active trials terminated
• Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis NCT02914535 · started 2017 · scored riskier than 96% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.